Cargando…

The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms

The acquired kinase mutation JAK2V617F plays a central role in myeloproliferative neoplasms (MPNs). However, the mechanisms responsible for the malignant hematopoietic stem/progenitor cell (HSPC) expansion seen in patients with MPNs are not fully understood, limiting the effectiveness of current tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhan, H, Lin, C H S, Segal, Y, Kaushansky, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783797/ https://www.ncbi.nlm.nih.gov/pubmed/28744010 http://dx.doi.org/10.1038/leu.2017.233

Ejemplares similares

JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury
por: Lin, Chi Hua Sarah, et al.
Publicado: (2018)

Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms
por: Stein, Brady L., et al.
Publicado: (2011)

Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm
por: Rahman, Mohammed Ferdous-Ur, et al.
Publicado: (2022)

Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm
por: Castiglione, Melissa, et al.
Publicado: (2020)

Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013)

Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
por: ZHANG, SHU-PENG, et al.
Publicado: (2015)

JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines
por: Nauroy, P, et al.
Publicado: (2014)

Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
por: Shi, Kaiyao, et al.
Publicado: (2014)

The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Reversine exhibits antineoplastic activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Lima, Keli, et al.
Publicado: (2019)

Hematopoietic fitness of JAK2(V617F) myeloproliferative neoplasms is linked to clinical outcome
por: Abu-Zeinah, Ghaith, et al.
Publicado: (2022)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013)

JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms
por: Elf, Shannon E.
Publicado: (2021)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
por: Allain-Maillet, Sophie, et al.
Publicado: (2020)

Metformin exerts multitarget antileukemia activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2018)

Expression of CD markers in JAK2(V617F) positive myeloproliferative neoplasms: Prognostic significance
por: Shahrabi, Saeid, et al.
Publicado: (2018)

Erythrocyte-derived microvesicles induce arterial spasms in JAK2(V617F) myeloproliferative neoplasm
por: Poisson, Johanne, et al.
Publicado: (2020)

Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2(V617F) mutation
por: Guy, Alexandre, et al.
Publicado: (2023)

Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2(V617F) mutation
por: Fan, Wenjuan, et al.
Publicado: (2023)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
por: Yönal-Hindilerden, İpek, et al.
Publicado: (2023)

The implication of identifying JAK2(V617F) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis
por: Olsen, Randall J., et al.
Publicado: (2008)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
por: Ferdowsi, Shirin, et al.
Publicado: (2016)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice
por: Yan, Dongqing, et al.
Publicado: (2015)

Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation
por: Bennemann, Karla, et al.
Publicado: (2012)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
por: Kalala, Fani, et al.
Publicado: (2012)

Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
por: Kim, Hye-Ran, et al.
Publicado: (2013)

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
por: Belcic Mikic, Tanja, et al.
Publicado: (2019)

Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Garbers, Christoph, et al.
Publicado: (2020)

Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

JAK2 p.(V617F) mutation in Tunisian myeloproliferative neoplasms and its genotype-phenotype correlation
por: Sassi, Hela, et al.
Publicado: (2021)

P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Novak, W., et al.
Publicado: (2022)

The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
por: Orbell, Lai Yee, et al.
Publicado: (2023)

A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm
por: Zhang, Haotian, et al.
Publicado: (2021)

Cigarette smoke stimulates clonal expansion of Jak2(V617F) and Tet2(-/-) cells
por: Ramanathan, Gajalakshmi, et al.
Publicado: (2023)

Protracted Clonal Trajectory of a JAK2 V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia
por: Langabeer, Stephen E., et al.
Publicado: (2018)

Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F
por: Lundberg, Pontus, et al.
Publicado: (2014)

JAK2 V617F-Dependent Upregulation of PU.1 Expression in the Peripheral Blood of Myeloproliferative Neoplasm Patients
por: Irino, Tamotsu, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_oqgd5nnbbq2ct3108j2mkuo3a2